Table 5.
Peak and mean uNGAL concentrations in survivors and nonsurvivors, by pRIFLEmax AKI strata
| Measurement (ng/mg creatinine) | Group (numbers of patients: survivors/nonsurvivors) | |||
| Control (31/3) | pRIFLEmax R (46/4) | pRIFLEmax I (25/6) | pRIFLEmax F (18/7) | |
| Peak uNGALa | ||||
| Survivors | 0.6 ± 1.8/0.1 (0.4) | 0.9 ± 1.4/0.4 (1.2) | 2.4 ± 3.5/0.8 (2.0) | 4.1 ± 3.7/2.7 (5.5) |
| Nonsurvivors | 0.4 ± 0.3/0.2 (0.5) | 1.8 ± 2.7/0.7 (3.2) | 2.7 ± 5.0/0.9 (1.0) | 2.8 ± 4.0/1.5 (1.8) |
| Mean uNGALa,b | ||||
| Survivors | 0.4 ± 1.3/0.1 (0.2) | 0.6 ± 0.8/0.3 (0.7) | 1.6 ± 2.5/0.5 (1.8) | 3.1 ± 3.1/2.2 (4.2) |
| Nonsurvivors | 0.3± 0.2/0.2 (0.4) | 1.1 ± 1.5/0.6 (2.1) | 1.8 ± 3.0/1.0 (1.1) | 1.9 ± 2.6/1.1 (1.1) |
Values are expressed as mean ± standard deviation/median (interquartile range). aPeak and mean urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations were not statistically significantly different between survivors and nonsurvivors in any of the pRIFLE strata (P > 0.05, Mann-Whitney test). bMean uNGAL refers to the mean of all 4 urine specimens collected for each patient. pRIFLEmax, the worst pRIFLE stratum attained; pRIFLE, pediatric modified Risk, Injury, Failure, Loss, End Stage Kidney Disease.